Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.radonc.2011.07.030
Title: Preoperative concomitant boost intensity-modulated radiotherapy with oral capecitabine in locally advanced mid-low rectal cancer: A phase II trial
Authors: Li, J.-L.
Ji, J.-F.
Cai, Y.
Li, X.-F.
Li, Y.-H.
Wu, H.
Xu, B.
Dou, F.-Y.
Li, Z.-Y.
Bu, Z.-D.
Wu, A.-W.
Tham, I.W.K. 
Keywords: Capecitabine
Intensity-modulated radiotherapy
Rectal cancer
Issue Date: Jan-2012
Citation: Li, J.-L., Ji, J.-F., Cai, Y., Li, X.-F., Li, Y.-H., Wu, H., Xu, B., Dou, F.-Y., Li, Z.-Y., Bu, Z.-D., Wu, A.-W., Tham, I.W.K. (2012-01). Preoperative concomitant boost intensity-modulated radiotherapy with oral capecitabine in locally advanced mid-low rectal cancer: A phase II trial. Radiotherapy and Oncology 102 (1) : 4-9. ScholarBank@NUS Repository. https://doi.org/10.1016/j.radonc.2011.07.030
Abstract: Purpose: We aimed to assess the safety and efficacy of preoperative intensity-modulated radiotherapy (IMRT) with oral capecitabine in patients with locally advanced mid-low rectal cancer using a concomitant boost technique. Materials and methods: Patients with resectable locally advanced mid-low rectal cancer (node-negative ≥T3 or any node-positive tumor) were eligible. The eligible patients received IMRT to 2 dose levels simultaneously (50.6 and 41.8 Gy in 22 fractions) with concurrent capecitabine 825 mg/m 2 twice daily 5 days/week. The primary end point included toxicity, postoperative complication, and pathological complete response rate (ypCR). The secondary endpoints included local recurrence rate, progression-free survival (PFS), and overall survival (OS). Results: Sixty-three eligible patients were enrolled; five patients did not undergo surgery. Of the 58 patients evaluable for pathologic response, the ypCR rate was 31.0% (95% CI 19.1-42.9). Grade 3 toxicities included diarrhea (9.5%), radiation dermatitis (3.2%), and neutropenia (1.6%). There was no Grade 4 toxicity reported. Four (6.9%) patients developed postoperative complications. Two-year local recurrence rate, PFS, and OS were 5.7%, 90.5%, and 96.0%, respectively. Conclusions: The design of preoperative concurrent boost IMRT with oral capecitabine could achieve high rate of ypCR with an acceptable toxicity profile. © 2011 Elsevier Ireland Ltd. All rights reserved.
Source Title: Radiotherapy and Oncology
URI: http://scholarbank.nus.edu.sg/handle/10635/125435
ISSN: 01678140
DOI: 10.1016/j.radonc.2011.07.030
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

37
checked on Aug 20, 2019

WEB OF SCIENCETM
Citations

32
checked on Aug 12, 2019

Page view(s)

34
checked on Aug 16, 2019

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.